Xilio Therapeutics, Inc.
XLO
$8.46
-$0.05-0.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.36M | -16.29M | -15.84M | -13.27M | -13.09M |
| Total Depreciation and Amortization | 323.00K | 340.00K | 381.00K | 497.00K | 376.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.35M | 16.50M | 3.69M | 1.54M | 1.52M |
| Change in Net Operating Assets | 5.66M | -18.05M | -2.70M | 40.21M | -2.96M |
| Cash from Operations | -2.00M | -17.50M | -14.48M | 28.98M | -14.16M |
| Capital Expenditure | -95.00K | 0.00 | -401.00K | -22.00K | -6.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -95.00K | 0.00 | -401.00K | -22.00K | -6.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 82.90M | 0.00 | 44.00K | 4.83M | 8.20M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -47.03M | -285.00K | 47.32M | -- | -- |
| Cash from Financing | 35.87M | -285.00K | 47.36M | 4.83M | 8.20M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 33.77M | -17.78M | 32.48M | 33.79M | -5.96M |